Current report filing

Cover

v3.23.3
Cover
Sep. 13, 2023
Cover [Abstract]  
Document Type 8-K/A
Amendment Flag true
Amendment Description EXPLANATORY NOTE   This amendment to the Current Report on Form 8-K filed by Titan Pharmaceuticals, Inc. (“Titan” or the “Company”) on September 18, 2023 is being filed to amend certain disclosures regarding the Certificate of Designations, Preferences and Rights of Series AA Convertible Preferred Stock. No other changes have been made to the Form 8-K.
Document Period End Date Sep. 13, 2023
Entity File Number 001-13341
Entity Registrant Name TITAN PHARMACEUTICALS, INC.
Entity Central Index Key 0000910267
Entity Tax Identification Number 94-3171940
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 400 Oyster Point Blvd.
Entity Address, Address Line Two Suite 505
Entity Address, City or Town South San Francisco
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94080
City Area Code 650
Local Phone Number 244-4990
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.001 per share
Trading Symbol TTNP
Security Exchange Name NASDAQ
Entity Emerging Growth Company false